2m 2m 2m 2m 2m 2m 2m
- $3.1MMarket Cap
- -87.49%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
SHUTTLE PHARM (SHPH)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 39
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
E.F. Hutton & Co. announced it served as exclusive M&A advisor and placement agent for Shuttle Pharmaceuticals Holdings' acquisition of United Dogecoin Inc., creating one of the largest publicly traded Dogecoin mining platforms. The transaction included a $9.6 million PIPE financing to support mining operations expansion with next-generation equipment.
05/07/2026, 2:02 PM • Benzinga
Shuttle Executes LOI with Molecule.ai
Shuttle Pharmaceuticals has signed a non-binding letter of intent to acquire Molecule.ai, an AI-driven drug discovery platform, for $10 million. The acquisition aims to leverage advanced machine learning models to accelerate pharmaceutical research and development.
10/10/2025, 10:20 AM • Benzinga
Peers
Statistics
MoreInformation as of 06/02/2026
Company Profile
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
Key Executives
- Michael Vander Hoek
- Christopher Robert Cooper
- Tyvin A. Rich
- Yuying Liang
- Milton Brown
Current Ownership Distribution
- Insiders2.7M (57.94%)
- Institutions1.5M (31.44%)
- Mutual Funds496,341 (10.62%)
- Other0 (0.00%)